Literature DB >> 32584996

Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age.

Jane C Lindsey1, Denise L Jacobson1, Hans M Spiegel2, Catherine M Gordon3, Rohan Hazra4, George K Siberry5.   

Abstract

No safety concerns were identified in a randomized, crossover study of alendronate/placebo in youth with perinatal HIV infection and low bone mineral density (BMD). BMD improved with 48 weeks of alendronate and continued to improve with an additional 48 weeks of therapy. Gains were largely maintained 48 weeks after stopping alendronate.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV infection; bisphosphonates; bone; children

Year:  2021        PMID： 32584996      PMCID： PMC7958836          DOI： 10.1093/cid/ciaa861

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  8 in total

1.  Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age.

Authors:  Denise L Jacobson; Jane C Lindsey; Catherine Gordon; Rohan Hazra; Hans Spiegel; Flavia Ferreira; Fabiana R Amaral; Jesica Pagano-Therrien; Aditya Gaur; Kathy George; Jane Benson; George K Siberry
Journal:  Clin Infect Dis       Date:  2020-08-22       Impact factor: 9.079

2.  Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life.

Authors:  Michael T Yin; Emily Lund; Jayesh Shah; Chiyuan A Zhang; Marc Foca; Natalie Neu; Kyle K Nishiyama; Bin Zhou; Xiangdong E Guo; John Nelson; David L Bell; Elizabeth Shane; Stephen M Arpadi
Journal:  AIDS       Date:  2014-01-28       Impact factor: 4.177

3.  The bone mineral density in childhood study: bone mineral content and density according to age, sex, and race.

Authors:  Heidi J Kalkwarf; Babette S Zemel; Vicente Gilsanz; Joan M Lappe; Mary Horlick; Sharon Oberfield; Soroosh Mahboubi; Bo Fan; Margaret M Frederick; Karen Winer; John A Shepherd
Journal:  J Clin Endocrinol Metab       Date:  2007-02-20       Impact factor: 5.958

4.  Bone mineral density in children and adolescents with perinatal HIV infection.

Authors:  Linda A DiMeglio; JiaJia Wang; George K Siberry; Tracie L Miller; Mitchell E Geffner; Rohan Hazra; William Borkowsky; Janet S Chen; Laurie Dooley; Kunjal Patel; Russell B van Dyke; Roger A Fielding; Yared Gurmu; Denise L Jacobson
Journal:  AIDS       Date:  2013-01-14       Impact factor: 4.177

5.  Peak bone mass in young HIV-infected patients compared with healthy controls.

Authors:  Eugènia Negredo; Pere Domingo; Elena Ferrer; Vicente Estrada; Adrià Curran; Antonio Navarro; Valentina Isernia; Joaquim Rosales; Núria Pérez-Álvarez; Jordi Puig; Anna Bonjoch; Patricia Echeverría; Daniel Podzamczer; Bonaventura Clotet
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

6.  Continuous antiretroviral therapy decreases bone mineral density.

Authors:  Birgit Grund; Grace Peng; Cynthia L Gibert; Jennifer F Hoy; Rachel L Isaksson; Judith C Shlay; Esteban Martinez; Peter Reiss; Fehmida Visnegarwala; Andrew D Carr
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

7.  The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients.

Authors:  Isabel Cassetti; José Valdez R Madruga; Jamal Muhamad A H Suleiman; Arnaldo Etzel; Lijie Zhong; Andrew K Cheng; Jeffrey Enejosa
Journal:  HIV Clin Trials       Date:  2007 May-Jun

8.  Dual energy X-Ray absorptiometry body composition reference values from NHANES.

Authors:  Thomas L Kelly; Kevin E Wilson; Steven B Heymsfield
Journal:  PLoS One       Date:  2009-09-15       Impact factor: 3.240
  8 in total
  1 in total

Review 1.  Osteoporosis and HIV Infection.

Authors:  Emmanuel Biver
Journal:  Calcif Tissue Int       Date:  2022-01-30       Impact factor: 4.000
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.